Outcomes of OROS® methylphenidate compared with atomoxetine in children with ADHD: A multicenter, randomized prospective study

Advances in Therapy

Volumn 22, Issue 5, 2005, Pages 498-512

  Kemner, Jason E ^a   Starr, H Lynn ^a   Ciccone, Patrick E ^a   Hooper Wood, Christa G ^a   Crockett, R Steve ^b  

^a McNeil Laboratories Inc   (United States)

^b DATA Inc   (United States)

Author keywords

ADHD; Atomoxetine; Attention deficit hyperactivity disorder; Community based study; Concerta; Methylphenidate; OROS MPH; School aged children; Stimulant; Strattera

Indexed keywords

AMPHETAMINE DERIVATIVE; ATOMOXETINE; METHYLPHENIDATE; OROS MPH; CENTRAL STIMULANT AGENT; PROPYLAMINE;

ABDOMINAL PAIN; ABNORMAL BEHAVIOR; AGGRESSION; ARTICLE; ATTENTION DEFICIT DISORDER; ATTENTION DEFICIT HYPERACTIVITY DISORDER RATING SCALE; CHILD; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; CRYING; DECREASED APPETITE; DIZZINESS; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG USE; EMOTIONAL DISORDER; EPIGASTRIC PAIN; EVALUATION; EXTENDED RELEASE FORMULATION; FATIGUE; FEMALE; HEADACHE; HUMAN; INSOMNIA; INTERVIEW; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; MOOD DISORDER; MULTICENTER STUDY; NAUSEA; OPEN STUDY; OUTCOME ASSESSMENT; OUTCOMES RESEARCH; PARENT; PHYSICIAN; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM; SIDE EFFECT; SOMNOLENCE; TELEPHONE; VOMITING; COMPARATIVE STUDY; TREATMENT OUTCOME;

ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; FEMALE; HUMANS; MALE; METHYLPHENIDATE; PROPYLAMINES; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 31144447046     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02849870     Document Type: Article

References (22)

1. American Academy of Pediatrics. Clinical practice guideline: diagnosis and evaluation of the child with attention-deficit/hyperactivity disorder. Pediatrics. 2000;105:1158-1170.
2. Greenhill LL, Pliszka S, Dulcan MK, et al. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry. 2002;41(suppl):26S-49S.
3. Goldman LS, Genel M, Bezman RJ, Slanetz PJ. Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents: Council on Scientific Affairs, American Medical Association. JAMA. 1998;279:1100-1107.
4. Perrin JM, Stein MT, Amler RW, et al. Clinical practice guideline: treatment of the school-aged child with attention-deficit/hyperactivity disorder. Pediatrics. 2001;108:1033-1044.
5. Wilens T, McBurnett K, Stein M, et al. ADHD treatment with once-daily OROS methylphenidate: final results from a long-term open-label study. J Am Acad Child Adolesc Psychiatry. 2005;44:1015-1023.
6. Pelham WE, Gnagy EM, Burrows-Maclean L, et al. Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings [abstract]. Pediatrics. 2001;107:E105.
7. Wolraich ML, Greenhill LL, Pelham W, et al. Randomized, controlled trial of OROS methylphenidate once a day in children with attention-deficit/ hyperactivity disorder. Pediatrics. 2001;108:883-892.
8. Michelson D, Allen AJ, Busner J, et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry. 2002;159:1896-1901.
9. Spencer T, Heiligenstein JH, Biederman J, et al. Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2002;63:1140-1147.
10. Kratochvil CJ, Heiligenstein JH, Dittmann R, et al. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial. J Am Acad Child Adolesc Psychiatry. 2002;41:776-784.
11. Ahmed SM, Beck B, Maurana CA, Newton G. Overcoming barriers to effective community-based participatory research in US medical schools. Educ Health (Abingdon). 2004;17:141-151.
12. Khanlou N, Peter E. Participatory action research: considerations for ethical review. Soc Sci Med. 2005;60:2333-2340.
13. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR). Washington, DC: American Psychiatric Association; 1994.
14. Faries DE, Yalcin I, Harder D, Heiligenstein JH. Validation of the ADHD rating scale as a clinician administered and scored instrument. J Atten Disord. 2001;5:107-115.
15. Guy W. ECDEU Assessment Manual for Psychophamacology. Rockville, Md: National Institutes of Health; 1976.
16. Wigal S, McGough JJ, McCracken JT, et al. A laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school-aged children with attention deficit/hyperactivity disorder. J Atten Disord. 2005;9:275-289.
17. Steinhoff KW, Wigal T, Swanson J. Single daily-dose ADHD medication treatment effect size evaluation. Poster presented at: 50th Anniversary Meeting of the American Academy of Child and Adolescent Psychiatry; October 14-19, 2003; Miami Beach, Fla.
18. Faraone SV. Understanding the effect size of ADHD medications: implications for clinical care. Medscape. 2003;8:1-7.
19. Crosby RD, Kolotkin RL, Williams GR. Defining clinically meaningful change in health-related quality of life. J Clin Epidemiol. 2003;56:395-407.
20. Swanson J, Gupta S, Lam A, et al. Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/ hyperactivity disorder. Arch Gen Psychiatry. 2003;60:204-211.
21. MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder: Multimodal Treatment Study of Children With ADHD. Arch Gen Psychiatry. 1999;56:1073-1086.
22. Michelson D, Adler L, Spencer T, et al. Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry. 2003;53:112-120.